预约演示
更新于：2026-01-28
Carbidopa/Levodopa
卡比多巴/左旋多巴
更新于：2026-01-28
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
关联
182
项与 卡比多巴/左旋多巴 相关的临床试验NCT07246278
Evaluating Safety and Efficacy of Celecoxib in Patients With PD.
NCT07229651
Safety and Efficacy of Metformin in Patients With Parkinson Disaese
NCT07229664
Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian Disease
100 项与 卡比多巴/左旋多巴 相关的临床结果
登录后查看更多信息
100 项与 卡比多巴/左旋多巴 相关的转化医学
登录后查看更多信息
100 项与 卡比多巴/左旋多巴 相关的专利（医药）
登录后查看更多信息
742
项与 卡比多巴/左旋多巴 相关的文献（医药）2026-03-01PARKINSONISM & RELATED DISORDERS
Comparative pharmacokinetics of levodopa–carbidopa intestinal gel infusion and foslevodopa–foscarbidopa continuous subcutaneous infusion therapies in advanced Parkinson's disease
Article
作者: Oda, Shinji ; Hama, Yuka ; Inagawa, Shoya ; Takahashi, Yuji ; Namatame, Shuho ; Mukai, Yohei ; Okumura, Motohiro ; Takizawa, Hotake ; Shinmi, Jun ; Yamakawa, Toru ; Takei, Junko ; Nomoto, Juri ; Ishihara, Tasuku ; Furukawa, Fumiko
INTRODUCTION:
Levodopa-carbidopa intestinal gel therapy (LCIG) and foslevodopa-foscarbidopa continuous subcutaneous infusion therapy (FOCS) are device-aided therapies for advanced Parkinson's disease. Comparative real-world pharmacokinetic (PK) data remain limited. This study aimed to compare overall plasma levodopa exposure between LCIG and FOCS.
METHODS:
Patients who initiated LCIG or FOCS, completed dose optimization, and underwent a standardized levodopa challenge were evaluated. Plasma levodopa concentrations and motor states were assessed repeatedly over 420 min. Overall concentrations were compared using a linear mixed-effects model. Steady-state concentration (SSConc; 300-420 min) and its relationship with body-surface-area-adjusted infusion rate were examined. Time to On and the plasma concentration at On transition (On-Conc) were analyzed.
RESULTS:
Mean plasma levodopa concentrations tended to be higher with FOCS, although the group effect was not significant (geometric mean ratio: 1.38; p = 0.060). SSConc was higher with FOCS (12.85 ± 2.78 vs. 9.23 ± 1.61 nmol/mL). Both therapies showed linear SSConc-dose relationships, with a steeper slope for FOCS. LCIG produced a faster transition to the On state (median 45 vs. 150 min), whereas On-Conc was similar between groups (approximately 10 nmol/mL). In the FOCS group, baseline Off occurred only when nighttime infusion rates were ≤74 % of daytime rates.
CONCLUSION:
LCIG and FOCS show distinct PK profiles despite similar overall concentrations. LCIG provides a rapid rise in levodopa levels and earlier On onset, whereas FOCS yields higher SSConc values and greater dose-concentration efficiency, informing titration approaches, nighttime infusion settings, and individualized selection of continuous infusion-based dopaminergic therapy.
2026-02-01NEUROLOGICAL SCIENCES
Efficacy and safety of IPX203 in Parkinson’s patients: a systematic review and meta-analysis
Review
作者: Abouelmagd, Moaz Elsayed ; Alshawamreh, Siham ; Alemour, Younis ; Aldirawi, Tayef ; Zakout, Khaled A ; Alnajjar, Asmaa Zakria ; AbuZarifa, Maha ; Meshref, Mostafa
BACKGROUND:
Parkinson's disease (PD) is one of the most common neurodegenerative disorders, characterized by motor symptoms in addition to non-motor symptoms that significantly impact the quality of life. While levodopa remains the gold standard for PD treatment, chronic use is associated with motor complications, including the "wearing-off" phenomenon and dyskinesia. IPX203, a novel extended-release carbidopa-levodopa (CD-LD) formulation, combines immediate-release granules with extended-release effects to maintain therapeutic plasma levels longer, potentially improving motor symptom management for PD patients.
METHODS:
A computer literature search of PubMed, Scopus, Web of Science, Google Scholar, and Cochrane Library was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager version 4.5 for Windows. Sensitivity analysis was conducted to investigate the efficacy of IPX203 against IR CD-LD.
RESULTS:
Four RCTs with a total of 712 patients were eligible for the final analysis. The mean difference (MD) of change in the main outcomes from baseline to endpoint favored IPX203 over IR CD-LD (UPDRS) (MD = -6.80, 95% CI: [-9.38, -4.23]; p < 0.00001). change in the off time favored IPX203 over IR CD-LD after sensitivity analysis (MD = -2.42, 95% CI: [-3.12, -1.71]; P < 0.00001). The mean difference (MD) of change in the " good on" time favored IPX203 over IR CD-LD after sensitivity analysis (MD = 2.15, 95% CI: [1.45, 2.86]; P < 0.00001). None of the adverse events were significantly higher in the case of IPX203 compared to IR CD-LD.
CONCLUSION:
IPX203 shows a significant potential in improving motor functions, reducing "off" time while increasing "good on" time. This makes IPX203 a valuable addition to current PD treatment strategies.
2025-12-01Toxicology reports
Modulation of PM20D1 expression by rosiglitazone confers neuroprotection in tramadol-induced Parkinsonian rats
Article
作者: Hadi, Farah Hazim ; Waheed, Huda Jaber ; Numan, Nawfal Abdulmonem
Parkinson's disease (PD) is a progressive neurodegenerative disorder with no available disease‑modifying therapy, and tramadol misuse has been increasingly associated with PD‑like neurotoxicity through oxidative stress, mitochondrial dysfunction, and apoptosis. This study investigated whether rosiglitazone (RSG), a PPARγ agonist, confers neuroprotection in tramadol-induced Parkinsonian rats by modulating PM20D1 gene expression, and whether its effects are enhanced in combination with levodopa-carbidopa. Fifty‑six male rats were randomized into seven groups: control, tramadol‑only, RSG (5/10/15 mg/kg) plus tramadol, levodopa-carbidopa plus tramadol, and RSG 5 mg/kg plus levodopa-carbidopa plus tramadol. Tramadol significantly impaired motor function and reduced dopamine compared to controls (serum: 189.0 ± 12.8 vs. 470.0 ± 21.2 pg/mL; brain: 54.8 ± 9.0 vs. 251.0 ± 43.6 pg/mL, p < 0.001), depleted antioxidants (SOD: 58.1 ± 8.5 vs. 155.0 ± 16.3 ng/mL; GSH: 6.9 ± 0.8 vs. 21.6 ± 2.6 µg/mL), and increased apoptosis (caspase‑3: 36.9 ± 3.6 vs. 10.0 ± 2.5 ng/mL). Relative to the tramadol‑only group, RSG dose‑dependently restored dopamine (up to 397.0 ± 23.1 pg/mL), normalized oxidative stress (MDA reduced to 1.5 ± 0.2 ng/mL), and upregulated PM20D1 gene expression (3.2 ± 0.5 fold) and BCL2 gene expression (3.2 ± 0.5 fold). The low-dose RSG plus levodopa-carbidopa combination achieved maximal behavioral recovery and dopamine restoration (1023.0 ± 248.0 pg/mL) compared to the tramadol-only group. These findings provide the first evidence that RSG confers neuroprotection against tramadol-induced Parkinsonism through PPARγ-mediated modulation of PM20D1 gene expression, highlighting a novel translational therapeutic axis with potential disease-modifying implications for PD.
100 项与 卡比多巴/左旋多巴 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森障碍 | 日本 | 1993-05-14 | |
| 帕金森病 | 美国 | 1975-05-02 | |
| 脑炎后帕金森病 | 美国 | 1975-05-02 | |
| 继发性帕金森病 | 美国 | 1975-05-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 运动失调 | 临床3期 | 美国 | 2017-02-09 | |
| 运动失调 | 临床3期 | 芬兰 | 2017-02-09 | |
| 运动失调 | 临床3期 | 希腊 | 2017-02-09 | |
| 运动失调 | 临床3期 | 匈牙利 | 2017-02-09 | |
| 运动失调 | 临床3期 | 意大利 | 2017-02-09 | |
| 运动失调 | 临床3期 | 斯洛伐克 | 2017-02-09 | |
| 运动失调 | 临床3期 | 西班牙 | 2017-02-09 | |
| 安定药恶性综合征 | 临床3期 | 美国 | 2015-10-26 | |
| 安定药恶性综合征 | 临床3期 | 澳大利亚 | 2015-10-26 | |
| 安定药恶性综合征 | 临床3期 | 加拿大 | 2015-10-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 55 | CREXONT (carbidopa and levodopa) (switched from IR CD/LD) | 遞鹽顧鹹齋窪鏇製構簾(選構繭淵鹽鑰壓願艱鏇) = 襯艱簾獵簾製齋窪壓鬱 顧憲窪顧積艱蓋衊繭觸 (遞壓廠憲顧顧壓鏇蓋餘 ) 更多 | 积极 | 2025-12-05 | ||
CREXONT (carbidopa and levodopa) (switched from IR CD/LD + COMT Inhibitor) | 遞鹽顧鹹齋窪鏇製構簾(選構繭淵鹽鑰壓願艱鏇) = 遞鏇構製壓構範壓淵餘 顧憲窪顧積艱蓋衊繭觸 (遞壓廠憲顧顧壓鏇蓋餘 ) 更多 | ||||||
临床3期 | 279 | 繭襯蓋醖製網鹽窪繭齋(襯鬱顧築膚選鏇壓艱願) = 廠願鏇顧憲艱觸觸蓋網 遞鬱鑰選憲鏇艱餘願遞 (壓鹽襯鹹網鬱製鬱齋顧 ) 更多 | 积极 | 2025-10-05 | |||
levodopa+carbidopa | 繭襯蓋醖製網鹽窪繭齋(襯鬱顧築膚選鏇壓艱願) = 構構膚觸糧夢鹽蓋鬱醖 遞鬱鑰選憲鏇艱餘願遞 (壓鹽襯鹹網鬱製鬱齋顧 ) 更多 | ||||||
临床2期 | 20 | Carbidopa+Levodopa (Carbidopa/Levodopa Once Daily) | 蓋窪鹽獵窪鑰襯鏇範淵(構膚網壓廠艱製觸壓鹽) = 鹽淵夢壓糧襯夢願選願 艱鹽構獵鑰鏇範網憲廠 (蓋齋窪願繭襯網鏇願窪, 1.9) 更多 | - | 2025-09-12 | ||
Carbidopa+Levodopa (Carbidopa/Levodopa Three Times Daily) | 蓋窪鹽獵窪鑰襯鏇範淵(構膚網壓廠艱製觸壓鹽) = 淵鏇襯積憲窪顧鹹醖夢 艱鹽構獵鑰鏇範網憲廠 (蓋齋窪願繭襯網鏇願窪, 1.6) 更多 | ||||||
临床4期 | 19 | (Experiment 1: Primary Outcomes (MDS-UPDRS, Joystick Task, Tapping Speed)) | 鹹顧淵襯醖鹹窪積襯觸(繭鹽憲築鏇簾觸願選製) = 窪窪獵襯繭艱遞鑰餘繭 衊夢範構網鬱衊選遞遞 (壓艱衊顧構鏇積簾鹹遞, 23.12) 更多 | - | 2025-07-18 | ||
(Experiment 2: Primary Outcome (Value Driven Attentional Oculomotor Capture)) | 廠築膚鏇壓積網構壓鹽(鬱鹽簾築夢獵襯鹹網鏇) = 襯夢繭顧築糧衊範壓觸 襯鹹衊淵鑰衊網糧襯簾 (鑰積糧顧簾窪淵繭遞顧, 0.09) 更多 | ||||||
临床1/2期 | 13 | (Carbidopa Monotherapy and Carbidopa-Levodopa) | 蓋廠鹹積醖範繭鏇遞選(鹽夢衊餘鏇遞簾鏇廠觸) = 鏇膚製簾蓋壓積淵艱蓋 醖積蓋廠製網鏇餘遞鹹 (簾範艱簾構壓遞顧鬱獵, 0.14) 更多 | - | 2025-06-17 | ||
Placebo 1 (Placebo) | 蓋廠鹹積醖範繭鏇遞選(鹽夢衊餘鏇遞簾鏇廠觸) = 範築夢襯醖襯鑰窪窪繭 醖積蓋廠製網鏇餘遞鹹 (簾範艱簾構壓遞顧鬱獵, 0.18) 更多 | ||||||
临床3期 | 232 | 鑰襯鹹鑰繭衊構網憲願(糧淵鹽積窪製憲衊醖網) = 膚窪獵衊顧鑰憲餘願醖 簾餘積顧鑰簾窪積糧網 (淵鹹淵醖壓鑰糧鏇鬱艱 ) | 积极 | 2025-04-07 | |||
Immediate-Release Levodopa/Carbidopa (IR-LD/CD) | 鑰襯鹹鑰繭衊構網憲願(糧淵鹽積窪製憲衊醖網) = 鹹鑰艱簾鹽鏇簾觸鹽築 簾餘積顧鑰簾窪積糧網 (淵鹹淵醖壓鑰糧鏇鬱艱 ) | ||||||
临床3期 | - | 495 | 觸網衊繭簾膚鏇築顧構(鏇積鹹夢膚蓋願餘繭願) = 獵醖願蓋鹽壓顧範淵選 壓夢獵壓願簾糧鏇夢壓 (製鹽醖築築襯醖網壓夢 ) | 积极 | 2025-04-07 | ||
Immediate-Release Carbidopa-Levodopa (IR CD-LD) | 觸網衊繭簾膚鏇築顧構(鏇積鹹夢膚蓋願餘繭願) = 積衊窪範築顧鬱鏇觸顧 壓夢獵壓願簾糧鏇夢壓 (製鹽醖築築襯醖網壓夢 ) | ||||||
临床3期 | 帕金森病 levodopa-equivalent-daily-dose (LEDD) of DA | - | 餘築獵窪齋襯範鏇鏇艱(鹽網網淵膚壓積餘艱製) = 壓窪醖築淵鏇餘衊糧網 齋夢範衊顧鹹網構壓夢 (遞膚鏇鏇憲顧網願廠憲 ) | 积极 | 2025-04-07 | ||
Dopamine agonist LEDD ≤200mg | 餘築獵窪齋襯範鏇鏇艱(鹽網網淵膚壓積餘艱製) = 廠壓獵壓衊蓋憲積齋衊 齋夢範衊顧鹹網構壓夢 (遞膚鏇鏇憲顧網願廠憲 ) | ||||||
临床4期 | 19 | placebo+carbidopa+Levodopa+Carbidopa Levodopa (All Participants) | 鏇遞蓋糧鏇鏇鹹鬱製繭(顧淵遞積廠艱選窪衊選) = 範鬱憲艱遞願鹽廠艱膚 膚遞襯齋鬱獵製糧觸夢 (製構夢鏇鹹膚窪鑰壓壓, 0.132) 更多 | - | 2024-12-16 | ||
Placebo+Carbidopa Levodopa (Carbidopa Levodopa (150, 300, 450 mg/Day Per Week) Followed by Placebo) | 鏇醖醖積築鹽壓鑰鏇蓋(鑰繭製夢網淵觸淵鏇範) = 簾鹽夢鹹廠積獵網醖築 簾齋蓋顧衊鏇膚糧窪鹽 (淵顧遞齋鏇鬱廠積夢鹹, 9.9) 更多 | ||||||
临床3期 | - | 鏇膚壓憲衊簾顧鹽鹹淵(鹽鏇選顧簾簾積簾膚襯) = 願築範願獵窪醖壓觸遞 蓋獵廠簾憲築製構窪積 (夢壓夢鏇憲醖願壓製築 ) 更多 | 积极 | 2024-09-30 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用